<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02179372</url>
  </required_header>
  <id_info>
    <org_study_id>EPA/CALPRO</org_study_id>
    <nct_id>NCT02179372</nct_id>
  </id_info>
  <brief_title>Eicosapentaenoic Free Fatty Acid and Fecal Calprotectin in Inflammatory Bowel Diseases</brief_title>
  <official_title>Modulation of Fecal Calprotectin by Eicosapentaenoic Free Fatty Acid in Inflammatory Bowel Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test Eicosapentaenoic free fatty acid's effects on calprotectin
      levels in IBD patients in clinical remission. During the study fecal calprotectin levels will
      be measured every 3 months and clinical flares will be registered.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in fecal calprotectin levels</measure>
    <time_frame>baseline, 3 months and at 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of clinical flares of diseases</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Ulcerative Colitis</condition>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Eicosapentaenoic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject with Cronn's Disease and/or Ulcerative colitis in clinical remission will receive 2 g/day of eicosapentaenoic acid for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium chain fatty acid (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects with Crohn's Disease and/or Ulcerative colitis will be receive 2 g/day of medium chain fatty acid for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Eicosapentaenoic acid</intervention_name>
    <description>30 subject with Crohn's Disease and/or Ulcerative Colitis in clinical remission but with fecal calprotectin value &gt;150 μg/g will recive 2 g/day of Eicosapentaenoic acid for 6 months treatment. At 3 months and 6 months, fecal calprotectin and clinical activity (CDAI for Crohn's Disease and SCCAI for Ulcerative Colitis) will be measured. The effect of Eicosapentaenoic acid on fecal calprotectin level will be monitored. Clinical relapses will be considered during the study.</description>
    <arm_group_label>Eicosapentaenoic acid</arm_group_label>
    <other_name>ALFA TM (S.L.A. Pharma A.G. Switzerland)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Medium chain fatty acid (placebo)</intervention_name>
    <description>30 subject with Crohn's Disease and/or Ulcerative Colitis in clinical remission but with fecal calprotectin value &gt;150 μg/g will recive 2 g/day of medium chain fatty acids for 6 months treatment. At 3 months and 6 months, fecal calprotectin and clinical activity (CDAI for Crohn's Disease and SCCAI for Ulcerative Colitis) will be measured.</description>
    <arm_group_label>Medium chain fatty acid (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ranged between18 and 80 years.

          -  Patients with Ulcerative Colitis (diagnosed on the base of clinic, endoscopic and
             histologic criteria) in clinical remission (SCCAI = 0) from at least 3 months and in
             stable therapy (without therapeutic modifications in the three previous months) with
             5-ASA, immunomodulators and/or biologics.

          -  Patients affected by Crohn's Disease (diagnosed on the base of clinic, endoscopic and
             histologic criteria) ) in clinical remission (CDAI &lt; 150) from at least 3 months and
             in stable therapy (without therapeutic modifications in the three previous months)
             with 5-ASA, immunomodulators and/or biologics.

          -  Fecal calprotectin at baseline &gt; 150 μg/g.

        Exclusion Criteria:

          -  Patients affected by Ulcerative Colitis and Crohn's Disease respectively with a SCCAI
             ≥ 1 and a CDAI ≥150.

          -  Patients on steroid therapy.

          -  Patients in therapy wih warfarin or other anticoagulants.

          -  Known or supposed ipersensitivity to eicosapentaenoic acid/omega 3.

          -  Women in fertile age which refuse to use contracceptives specified in the study (oral
             contraception, IUD) and breastfeed women.

          -  Patients with severe clinical conditions which the investigator consider to
             controindicate patient partecipation at the study.

          -  Therapy modifications and/or assumption of sperimental therapies within three months
             before the study inclusion.

          -  Patients unable to follow protocol procedures and to sign the informate consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Policlinico Sant'Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2014</study_first_submitted>
  <study_first_submitted_qc>June 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2014</study_first_posted>
  <last_update_submitted>November 28, 2016</last_update_submitted>
  <last_update_submitted_qc>November 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</investigator_affiliation>
    <investigator_full_name>andrea belluzzi, MD phD</investigator_full_name>
    <investigator_title>Consultant in Gastroenterology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

